These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
301 related articles for article (PubMed ID: 36157535)
1. Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis. Risaliti M; Bartolini I; Campani C; Arena U; Xodo C; Adotti V; Rosi M; Taddei A; Muiesan P; Amedei A; Batignani G; Marra F World J Gastroenterol; 2022 Aug; 28(29):3981-3993. PubMed ID: 36157535 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of Adjuvant Transarterial Chemoembolization after Radical Hepatectomy in Solitary Hepatocellular Carcinoma Patients: A Retrospective Study. Zeng G; Zou B; Li Y; Lin E; Liu X; Li P; Chen J; Zhang B; Jia Y; Cai C; Li J J Invest Surg; 2022 Jun; 35(6):1208-1216. PubMed ID: 35078386 [No Abstract] [Full Text] [Related]
3. Comparison of long-term survival of patients with solitary large hepatocellular carcinoma of BCLC stage A after liver resection or transarterial chemoembolization: a propensity score analysis. Zhu SL; Ke Y; Peng YC; Ma L; Li H; Li LQ; Zhong JH PLoS One; 2014; 9(12):e115834. PubMed ID: 25541684 [TBL] [Abstract][Full Text] [Related]
4. Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study. Peng Z; Wei M; Chen S; Lin M; Jiang C; Mei J; Li B; Wang Y; Li J; Xie X; Kuang M Eur Radiol; 2018 Aug; 28(8):3522-3531. PubMed ID: 29536241 [TBL] [Abstract][Full Text] [Related]
5. Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma. Chen S; Jin H; Dai Z; Wei M; Xiao H; Su T; Li B; Liu X; Wang Y; Li J; Shen S; Zhou Q; Peng B; Peng Z; Peng S Cancer Med; 2019 Apr; 8(4):1530-1539. PubMed ID: 30864247 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China. Wu Z; Cui L; Qian J; Luo L; Tu S; Cheng F; Yuan L; Zhang W; Lin W; Tang H; Li X; Li H; Zhang Y; Zhu J; Li Y; Xiong Y; Hu Z; Peng P; He Y; Liu L; He K; Shen W BMC Cancer; 2023 Apr; 23(1):325. PubMed ID: 37029339 [TBL] [Abstract][Full Text] [Related]
7. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study. Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002 [TBL] [Abstract][Full Text] [Related]
8. Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis. Lin CW; Chen YS; Lo GH; Hsu YC; Hsu CC; Wu TC; Yeh JH; Hsiao P; Hsieh PM; Lin HY; Shu CW; Hung CM BMC Gastroenterol; 2020 Apr; 20(1):99. PubMed ID: 32272898 [TBL] [Abstract][Full Text] [Related]
9. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization. Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739 [TBL] [Abstract][Full Text] [Related]
10. Liver resection versus transarterial chemoembolization for huge hepatocellular carcinoma: a propensity score matched analysis. Bogdanovic A; Bulajic P; Masulovic D; Bidzic N; Zivanovic M; Galun D Sci Rep; 2021 Feb; 11(1):4493. PubMed ID: 33627697 [TBL] [Abstract][Full Text] [Related]
11. The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study. Wang L; Lin N; Lin K; Xiao C; Wang R; Chen J; Zhou W; Liu J J Gastrointest Surg; 2021 May; 25(5):1172-1183. PubMed ID: 32440804 [TBL] [Abstract][Full Text] [Related]
12. Comparison of hepatic resection and transarterial chemoembolization for UICC stage T3 hepatocellular carcinoma: a propensity score matching study. Zhong C; Zhang YF; Huang JH; Xiong CM; Wang ZY; Chen QL; Guo RP BMC Cancer; 2018 Jun; 18(1):643. PubMed ID: 29879928 [TBL] [Abstract][Full Text] [Related]
13. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study. Chen J; Lai L; Lin Q; Huang W; Cai M; Zhu K; Huang M Oncotarget; 2017 Jan; 8(1):408-417. PubMed ID: 27880724 [TBL] [Abstract][Full Text] [Related]
14. Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis. Kim DS; Lim TS; Jeon MY; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baatarkhuu O; Kim SU Dig Dis Sci; 2019 Dec; 64(12):3660-3668. PubMed ID: 31187326 [TBL] [Abstract][Full Text] [Related]
15. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005 [TBL] [Abstract][Full Text] [Related]
16. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization. Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295 [TBL] [Abstract][Full Text] [Related]
17. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching. Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976 [TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma. Kim JY; Sinn DH; Gwak GY; Choi GS; Saleh AM; Joh JW; Cho SK; Shin SW; Carriere KC; Ahn JH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW Clin Mol Hepatol; 2016 Jun; 22(2):250-8. PubMed ID: 27377909 [TBL] [Abstract][Full Text] [Related]
19. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis. Yang Y; Lin K; Liu L; Qian Y; Yang Y; Yuan S; Zhu P; Huang J; Liu F; Gu F; Fu S; Jiang B; Liu H; Pan Z; Lau WY; Zhou W Cancer Med; 2021 Mar; 10(6):2100-2111. PubMed ID: 33650288 [TBL] [Abstract][Full Text] [Related]
20. Survival benefit of liver resection following complete response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: a retrospective, multicenter, cohort study. Hu Z; Wang X; Fu Y; Yang D; Zhou Z; Chen M; Song X; Zhang Y Int J Surg; 2024 Feb; 110(2):1019-1027. PubMed ID: 38006301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]